Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.38 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.38 |
| ▸ | TLR2 | O60603 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482395 | 0.98 | DNM1 (0.50) | DNM1LPAR1LPAR3LPAR2CNR1 | |
| SCHEMBL28019342 | 0.92 | DNM1 (0.53) | DNM1LPAR1LPAR3LPAR2CNR1 | |
| SCHEMBL4490936 | 0.91 | DNM1 (0.42) | DNM1LPAR1LPAR3LPAR2CNR1 | |
| SCHEMBL4495268 | 0.89 | DNM1 (0.50) | DNM1LPAR1LPAR3LPAR2CNR1 | |
| SCHEMBL4498566 | 0.89 | DNM1 (0.50) | DNM1LPAR1LPAR3LPAR2CNR1 | |
| SCHEMBL27900394 | 0.88 | DNM1 (0.48) | DNM1LPAR1LPAR3LPAR2CNR1 | |
| SCHEMBL22654529 | 0.87 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2CNR1 | |
| SCHEMBL22654528 | 0.87 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2CNR1 | |
| SCHEMBL9469822 | 0.86 | DNM1 (0.48) | DNM1LPAR1LPAR3LPAR2CNR1 | |
| SCHEMBL29221553 | 0.86 | DNM1 (0.48) | DNM1LPAR1LPAR3LPAR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180108947-A9 | ELECTROLYTE AND LITHIUM-ION BATTERY CONTAINING THE SAME | NINGDE AMPEREX TECHNOLOGY LTD. (CN) | 2018-04-19 | — | — | US | disclosed |
| US-20170084956-A1 | ELECTROLYTE AND LITHIUM-ION BATTERY CONTAINING THE SAME | Amperex Technology Limited (CN) | 2017-03-23 | — | — | US | disclosed |
| EP-1084710-B1 | ADENOSINE A1 ANTAGONISTS FOR MALE STERILITY | ASTELLAS PHARMA INC (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | disclosed |
| US-6521656-B1 | Contacting sperm with a pyrazolo(1,5-a)pyridine acrosomal reaction induction promoter then joining with ovum | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-0925299-B1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-0823254-B1 | NOVEL USE OF PYRAZOLOPYRIDINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-07-17 | — | — | EP | disclosed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6355640-B1 | TREATMENT OF HYPERTENSION, UROGENITAL DISORDERS AND FORMED BY WITTIG REACTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-5102878-A | Treating psychological, bone, cardiovascular, blood disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5102869-A | Urogenital disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5087629-A | Diuretics, hypotensive agents; cardiotonic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| US-4994453-A | Treating asthma, diabetes, obesity, immunosuppression | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| US-4985444-A | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| CN-1044656-A | Pyrazolopyridine compound and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1990-08-15 | — | — | CN | disclosed |
| US-4925849-A | DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| CN-1031376-A | Pyrazolopyridine compound and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1989-03-01 | — | — | CN | disclosed |
| EP-0299209-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | ADORA2A, ADORA1, ADORA2B | DNM1 1124/4885LPAR1 106/4885LPAR3 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.